AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22772053
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (up to 190 mg once a day)
Trial: 22772053
Drug: Ivabradine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (up to 7.5 mg twice daily)
Trial: 18037672
Drug: Esmolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1 mg kg(‐1) bolus and infusion of 5‐10 microg kg(‐1) min(‐1))
Trial: 16431932
Drug: Blood withdrawal
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood withdrawal (450 ml)
Trial: 10881828
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg intravenously)
Trial: 8418243
Drug: Oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate 1,600 mg/d
Trial: 2868413
Drug: Intranasal gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days)
Trial: 29535135
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump (SAP) insulin delivery
Trial: 29535135
Drug: SAP insulin
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP insulin delivery
Trial: 25037033
Drug: Heptavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent vaccine
Trial: 25037033
Drug: Hexavalent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent and monovalent MenC control vaccines
Trial: 20299307
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg daily for 4 days with a gap of 10 days, total 24 courses for 48 weeks)
Trial: 20299307
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C tablet (non-chewable, same dosage schedule as azithromycin)
Trial: 18716298
Drug: Adalimumab (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (24 mg/m², max 40 mg, subcutaneously every other week for 16 weeks)
Trial: 8756373
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride 0.6 mg three times daily
Trial: 8756373
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride 1 mg twice daily
Trial: 8756373
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride 2 mg twice daily
Trial: 8756373
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride (all doses combined)
Trial: 7234694
Drug: Aspirin (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (4.0 g/day)
Trial: 30721159
Drug: Body weight‐adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight‐adapted CM protocol (0.4 g I/kg dosing factor, TIL adapted to weight)
Trial: 30721159
Drug: Fixed CM
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed CM dose (33 g I, 110 mL volume)
Trial: 26865200
Drug: Thiazide prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide prescription
Trial: 26865200
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent prescription
Trial: 22985437
Drug: Normal-PI (NPI:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-PI (NPI: 1.0 g/kg/day)
Trial: 22985437
Drug: High-PI (HPI:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-PI (HPI: 1.2 g/kg/day)
Trial: 17719932
Drug: High-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibuprofen (20 to 30 mg/kg/twice daily, adjusted to a peak serum concentration of 50 to 100 mug/mL)
Trial: 17719932
Drug: High-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibuprofen
Trial: 11133596
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intrathecal morphine and sufentanil
Trial: 11133596
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine (patient-controlled analgesia)
Trial: 9036884
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) treatment at two atmospheres of pressure for 90 minutes twice a day for a minimum of 10 treatments
Trial: 7944639
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of hyaluronan (Hyalgan) in 2 ml of buffered saline, administered weekly for 5 weeks
Trial: 7944639
Drug: Hyalgan (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyalgan (treatment group)
Trial: 2979277
Drug: Ranitidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administration at 18.00 hours
Trial: 2979277
Drug: Ranitidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administration at 22.00 hours
Trial: 2979277
Drug: Ranitidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administration with food
Trial: 2979277
Drug: Ranitidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administration without food
Trial: 2979277
Drug: Ranitidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administration at both times
Trial: 30453344
Drug: Metoclopramide co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide co-administration
Trial: 24043395
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise (HIGH; 600 kcal/day)
Trial: 22716224
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg (oral capsule)
Trial: 17184595
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I)
Trial: 14529680
Drug: 3-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-h infusion of paclitaxel
Trial: 14529680
Drug: 6-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-h infusion of paclitaxel
Trial: 14529680
Drug: 24-h infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h infusion of paclitaxel
Trial: 14529680
Drug: 3-h vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-h vs 6-h infusion regimens
Trial: 6197766
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) at a constant dose of 8 ng kg‐1 min‐1
Trial: 26800392
Drug: Riluzole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (50 mg/bid) plus citalopram (40 mg/day)
Trial: 26800392
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus citalopram (40 mg/day)
Trial: 22426408
Drug: Paclitaxel/carboplatin weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel/carboplatin weekly (60 mg/m2 paclitaxel and AUC 2.7 carboplatin)
Trial: 22426408
Drug: Treatment adjustments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adjustments due to toxicity
Trial: 7655109
Drug: Flutrimazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutrimazole 1% cream applied once a day
Trial: 7655109
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% cream applied once a day
Trial: 31897949
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 2000 IU (50 μg) daily for 12 weeks
Trial: 30303923
Drug: Elagolix alone
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix alone (300 mg twice daily)
Trial: 30303923
Drug: Elagolix with
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate
Trial: 30303923
Drug: Elagolix with
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate
Trial: 26975346
Drug: 50,000 U
RxNorm normalized name: Decara 50,000 UNT Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 U oral cholecalciferol monthly (Group A)
Trial: 26975346
Drug: 50,000 U
RxNorm normalized name: Decara 50,000 UNT Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 U oral cholecalciferol bimonthly (Group B)
Trial: 24308540
Drug: Garlic (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic (three garlic tablets orally, twice daily for 14 days)
Trial: 24308540
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three placebo tablets orally, twice daily for 14 days)
Trial: 22137103
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) in postmenopausal women after six months
Trial: 16928534
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of 120 mL autologous blood into the apical chest drain on the fifth postoperative day, with additional doses on days 7 and 9 if necessary
Trial: 16928534
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of 120 mL autologous blood
Trial: 10960201
Drug: 0.2% ropivacaine/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine/2 microg/mL fentanyl
Trial: 1498533
Drug: application-impulse stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application-impulse stimulation treatment
Trial: 6474383
Drug: Verapamil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (4 mg)
Trial: 24980612
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray (24 IU B.I.D for participants 16 years and over; 18 IU B.I.D for participants 13-15 years; increased to 40 IU B.I.D for participants 16 years and over; 32 IU B.I.D for participants 13-15 years)
Trial: 17350803
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with chamomile infusion sweetened with panela
Trial: 10594400
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m. or b.d. for 1 month plus 500 mg clarithromycin (b.d.) and 200 mg furazolidone (b.d.) for 1 week
Trial: 10594400
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg (not specified in the intervention but mentioned in results)
Trial: 2099197
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg twice daily for seven days
Trial: 2099197
Drug: Triple tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple tetracycline 300 mg twice daily for two weeks
Trial: 7425389
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metaproterenol (M) and Theophylline (T)
Trial: 30968336
Drug: TA‐ER 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA‐ER 32 mg
Trial: 27884686
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 10 mL lidocaine 1% (100 mg) mixed with polyvinyl alcohol particles (355‐500 μm)
Trial: 27884686
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 10 mL lidocaine 1% (100 mg) injected after embolization
Trial: 19730391
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 or 10 mg/d) + Olmesartan medoxomil (10, 20, or 40 mg/d)
Trial: 3688150
Drug: Group occupational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group occupational therapy
Trial: 24076297
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/day for 5 days (n = 1498)
Trial: 20228710
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment for HD
Trial: 20228710
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for HD
Trial: 12721773
Drug: Ciprofloxacin formulations
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin formulations stored under class IV conditions (40 degrees C, 75% relative humidity)
Trial: 12721773
Drug: Diclo 50
RxNorm normalized name: Xiclo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclo 50 (Camden) and Dicloflame 50 (Intas) formulations stored under class IV conditions
Trial: 12721773
Drug: Ciprofloxacin formulations
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin formulations stored at ambient conditions
Trial: 12721773
Drug: Diclo 50
RxNorm normalized name: Xiclo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclo 50 (Camden) and Dicloflame 50 (Intas) formulations stored at ambient conditions
Trial: 9230725
Drug: Regular anthelminthic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular anthelminthic treatment with albendazole for 1 year
Trial: 9230725
Drug: Regular anthelminthic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular anthelminthic treatment with albendazole
Trial: 3629189
Drug: Graded fundic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded fundic distension with a balloon to 150 ml
Trial: 3629189
Drug: Graded fundic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded fundic distension with a balloon to 300 ml
Trial: 3629189
Drug: Graded fundic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded fundic distension with a balloon to 600 ml
Trial: 3629189
Drug: Continuous fundic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous fundic distension with a volume of 300 ml for 2 1/2 h
Trial: 3629189
Drug: Anticholinergic drug
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drug benzilonium bromide during 30 min of fundic distension to 150 ml
Trial: 29351007
Drug: Early renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early renal replacement therapy (RRT) initiation strategy
Trial: 29351007
Drug: Delayed renal
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed renal replacement therapy (RRT) initiation strategy
Trial: 28103388
Drug: Low-dose retinol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose retinol (0.02%) + Climbazole (0.5%)
Trial: 21570513
Drug: Abciximab (abx)
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab (abx) combination therapy
Trial: 18285668
Drug: Oseltamivir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir treatment for influenza A
Trial: 18285668
Drug: Oseltamivir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir treatment for influenza B
Trial: 12967058
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 10 mg/day
Trial: 11034112
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (1 mg)
Trial: 31970414
Drug: HDAC8 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HDAC8 inhibitor
Trial: 21211891
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment (Class 2b)
Trial: 21211891
Drug: Closed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed treatment (Class 2a)
Trial: 19370950
Drug: Doxofylline (400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxofylline (400mg twice daily)
Trial: 12360456
Drug: Alosetron (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (1-4 mg twice daily)
Trial: 10486645
Drug: Caucasian women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caucasian women (CC)
Trial: 8735683
Drug: Medroxyprogesterone 10
RxNorm normalized name: medroxyprogesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone 10 mg
Trial: 1748539
Drug: labetalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (400 mg to 600 mg per day)
Trial: 26798966
Drug: LY900009 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY900009 at 30 mg
Trial: 26798966
Drug: LY900009 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY900009 at 15 mg
Trial: 24687576
Drug: Pre-warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-warmed intravenous fluids (approximately 41 °C)
Trial: 24687576
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature intravenous fluids
Trial: 19320679
Drug: Immediate postal
RxNorm normalized name: APPLE 500 mg in 50 mL TOPICAL SOLUTION [Mostal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate postal treatment for 3 months
Trial: 19320679
Drug: Delayed postal
RxNorm normalized name: APPLE 500 mg in 50 mL TOPICAL SOLUTION [Mostal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed postal treatment (months 3-6)
Trial: 11150109
Drug: Fludrocortisone acetate,
RxNorm normalized name: Fludrocortisone Acetate, 0.1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone acetate, titrated to 0.1 mg/d (n = 50)
Trial: 12045581
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg intravenously)
Trial: 7946179
Drug: Isradipine at
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine at 2.5 mg/day
Trial: 7946179
Drug: Nitrendipine at
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine at 10 mg/day
Trial: 7946179
Drug: Nitrendipine at
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine at 10 mg/day + Aspirin at 100 mg/day
Trial: 7946179
Drug: Isradipine at
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine at 2.5 mg/day + Aspirin at 100 mg/day
Trial: 3182156
Drug: Moderate-protein (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-protein (0.8 g.kg‐1.d‐1), high-carbohydrate hypoenergy diet (MP/HC)
Trial: 3182156
Drug: High-protein (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein (1.6 g.kg‐1.d‐1), moderate-carbohydrate hypoenergy diet (HP/MC)
Trial: 31311598
Drug: PCV7 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (3 doses)
Trial: 24013347
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with accelerated rehabilitation protocol
Trial: 19061152
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg t.i.d for 20 weeks
Trial: 12866134
Drug: Beta-blockers (control)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (control)
Trial: 10370677
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus high-dose, intermittent IL-2 (2.1 x 10(6) U twice weekly)
Trial: 10370677
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus low-dose, continuous IL-2 (7 x 10(5) U daily)
Trial: 8912507
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fluoxetine and Amitriptyline
Trial: 1676832
Drug: Idazoxan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (40 mg tid)